Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers (PDF 5.19 MB)

  Published:

  17 August 2022

• Final appraisal determination committee papers (PDF 2.53 MB)

  Published:

  17 August 2022